In this episode of The Purposeful Strategist, Belden Menkus speaks with Juho Jalkanen, CEO of Faron, a biotechnology company on a mission to bring cutting-edge immunotherapy to as many patients as possible, currently focused on difficult-to-treat cancers.

In their conversation, they discuss:

· How immunotherapy uses the patient's own immune system to attack disease, and why that makes it such a promising treatment.

· Faron's business strategy, rooted in absorbing the financial risk of scientific research, and how they keep pharmaceutical partners updated as they "de-risk" the product through clinical trials.

· Why Faron's steadfast commitment to research, rather than shedding it for a safer business case, as many biotech companies do, is its greatest commercial asset.

· Juho's own path from vascular surgeon to CEO, rooted in his desire to help as many patients as possible.

Faron: https://faron.com/

Menkus & Associates: https://www.menkus.com/

Supported by Norman Broadbent: https://www.normanbroadbent.com/

Belden Menkus is the Managing Director of Menkus & Associates, the strategy firm for businesses with a broader purpose. His McKinsey training combined with more than 30 years working at Board and ExCo level gives him both the analytical rigour and the insight that complex, high-stakes leadership situations demand.

Belden hosts The Purposeful Strategist, a weekly podcast. It explores how senior leaders bring purpose to life through strategy.